Elecsys® GAAD

Elecsys® GAAD test for the aid in diagnosis of early-stage HCC

Tune in to help save lives

Heptocellular Carcinoma (HCC) is a "silent killer". It develops unseen, often only to be found when it’s too late to save patients. It is already the third leading cause of cancer death,1 and the global incidence of HCC is increasing, especially in developed countries.2

But it doesn’t have to be that way. We refuse to let it continue as a "silent killer". We’re turning up the volume on HCC.

Healthcare is rapidly shifting, towards more personalised care that’s more in tune with patients, embracing digital technologies that enable new possibilities. At Roche, we are shaping a new class of diagnostic algorithms.

Introducing the Elecsys® GAAD in-vitro diagnostic multivariate index assay. It is a CE-marked algorithm to help you diagnose early stage HCC and save lives. Combining Elecsys® AFP and Elecsys® PIVKA-II assay results, along with gender and age, Elecsys® GAAD communicates patients’ risk factor clearly, so you may be able to evaluate earlier and save more lives.

It’s simple and intuitive to use, and can be adapted to your current workflow, so there will be no disruption to you.

Elecsys® GAAD is an in vitro diagnostic multivariate index assay intended to provide a semi-quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP assay and Elecsys® PIVKA‑II assay in human serum and plasma with gender and age. Elecsys® GAAD is intended as an aid in diagnosis of early stage Hepatocellular Carcinoma (HCC). 

Elecsys® GAAD is indicated for adults who meet the following criteria: diagnosis of chronic liver disease and recommended for surveillance due to increased risk of developing HCC. 

Elecsys® GAAD must be interpreted in conjunction with other diagnostic findings and clinical information in accordance with standard clinical management guidelines.


Crystal clear

Elecsys® GAAD gives you an easy-to-understand and accurate risk score3

icons approved


Elecsys® GAAD is a CE-marked digital tool for aid in diagnosis of early stage HCC

icon integrated

Can be seamlessly integrated

Can be integrated to your LIS easily with your current workflow

icon partnership

Committed partner

Trust Roche to help STOP Chronic Liver Disease

Laptop screen

navify® Marketplace

Find the digital products and services you need

Elecsys GAAD

HCC detection that’s in sync with your workflow

Ending the silence

HCC is often diagnosed in its advanced stages – when 5 year survival rates can be as low as 5%4 – because early stages are asymptomatic, and it can be difficult to gauge each patient’s risk factor. 

HCC develops in patients with chronic liver disease5, but this can happen at any stage over up to 30 years.6

Amplifying your confidence

We engineered the Elecsys® GAAD to be truly simple and speedy to set-up and use. However, you’re never alone. We have created support materials to aid your interpretations and ensure that you are always confident in your next step.

Contact us to Register your Interest

Amplifies the effectiveness of AFP

Ultrasound will always be a useful tool in HCC diagnosis. However, it has its limitations; readings can be compromised by obesity, fibrotic changes, and even the quality of device or user experience.7-9

But combining ultrasound with HCC-specific biomarkers, as Elecsys® AFP does, increases sensitivity for detecting early-stage HCC.10

Furthermore, the performance of Elecsys® AFP can be improved by including this biomarker in Elecsys® GAAD together with Elecsys® PIVKA-II, gender and age. Elecsys® GAAD showed a higher performance of detecting early stage HCC.13

Instant result of GAAD score

Elecsys® GAAD is a simple yet sophisticated algorithm. 

All you need to do enter 4 simple patient data points3 into the calculator, and in an instant you’ll be given a result: a risk-factor score from 0-10, to accurately predict how likely that patient is to develop HCC.3 The score is accompanied by a built-in result interpretation to help guide your next clinical decision.

icon ultrasound

Ultrasound alone12 45%

icon sensitivity

Elecsys® GAAD provides high sensitivity and high specificity3

icon ultrasound plus

Ultrasound + AFP12 63%

icon age


icon AFP result

Elecsys® AFP result

icon gender


icon PIVKA-II result

Elecsys® PIVKA-II result

Clinical performance of Elecsys® AFP and Elecsys® GAAD in early-stage HCC13

View Full Table

Clinical performance of Elecsys® AFP and Elecsys® GAAD in early-stage HCC13

  Early-stage HCC CLD controls
Elecsys assay/algorithm (cut-off) Sensitivity AUC b) Specificity a)
AFP (20 ng/ml) 36.4(27.4-46.3) 82.4 % (77.4-87.5) 98.2(95.4-99.5)
GAAD (2.57) 72.9(63.4-81.0) 91.3 % (88-94.6%) 92.2(87.9-95.4)
a) Clinical performance of Elecsys® AFP and Elecsys® GAAD for the detection of early-stage HCC [all results shown as % (95% CI)].
b) Area under the curve (AUC) of the Elecsys® AFP and Elecsys® GAAD for discriminating between disease controls and early-stage HCC patients

PRECAUTION: Assay results from other manufacturers have not been validated for the use of the Elecsys® GAAD test. The Elecsys® GAAD test should not be used without an independent clinical/radiological evaluation for the diagnosis of Hepatocellular Carcinoma (HCC). For each Elecsys® GAAD determination the measurement of the Elecsys® AFP and Elecsys® PIVKA-II assays must be determined from the same sample and measurement performed on the same analyzer type (either on cobas e 402, cobas e 411, cobas e 601, cobas e 602 or cobas e 801 analyzers).

Elecsys GAAD  treatments

  1. Kao Wei-Yu, et al. Medicine Baltimore 2015;94(43):e1929. 
  2. Fitzmaurice T, et al. JAMA Onco 2017;3(12):1683–1691.  
  3. Elecys GAAD Method Sheet. Reference: 09342192001.
  4. El-Serag HB, et al. Ther Adv Gastroenterol 2011;4(1):5–10.  
  5. Llovet JM, et al. Nat Rev Dis Prim 2016;2:16018. 
  6. El-Serag HB, et al. Hepatology 2002;36:S74–S83. 
  7. EASL Clinical Practice Guidelines: Management of hepatocellular carnoma. Journal of Hepatology 2017;69(1):182–236.  
  8. Simmons O, et al. Ailment Pharmacol Ther 2017;45:169–177.  
  9. Sherman M. Hepat Oncol 2014;1(2):161–163. 
  10. Tzartzeva K, et al. Gastroenterology 2018;145(6):1706–1718.  
  11. Henry L Y Chan et al. JGH Open: An open access journal of gastroenterology and hepatology 2022;6 292–300
  12. Yan JD, et al. Cancer Epidemiol Biomarkers Prev 2019;28(3):531–538. 
  13. Chan et al. (2022) ILC London 2022; https://bit.ly/3wMJV6k